JP2022508953A - Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 - Google Patents
Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 Download PDFInfo
- Publication number
- JP2022508953A JP2022508953A JP2021547054A JP2021547054A JP2022508953A JP 2022508953 A JP2022508953 A JP 2022508953A JP 2021547054 A JP2021547054 A JP 2021547054A JP 2021547054 A JP2021547054 A JP 2021547054A JP 2022508953 A JP2022508953 A JP 2022508953A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- mmol
- pyrazole
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 178
- 238000011282 treatment Methods 0.000 title description 24
- 238000000034 method Methods 0.000 claims abstract description 82
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 208000015181 infectious disease Diseases 0.000 claims abstract description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 12
- -1 L 1 is a bond Chemical group 0.000 claims description 319
- 125000000217 alkyl group Chemical group 0.000 claims description 131
- 125000003545 alkoxy group Chemical group 0.000 claims description 70
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- JKRDADVRIYVCCY-ZETCQYMHSA-N (2s)-2-hydroxyoctanoic acid Chemical compound CCCCCC[C@H](O)C(O)=O JKRDADVRIYVCCY-ZETCQYMHSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 353
- 239000000203 mixture Substances 0.000 description 236
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 136
- 239000007787 solid Substances 0.000 description 136
- 239000000243 solution Substances 0.000 description 135
- 235000019439 ethyl acetate Nutrition 0.000 description 126
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 90
- 238000006243 chemical reaction Methods 0.000 description 74
- 239000003208 petroleum Substances 0.000 description 68
- 238000010898 silica gel chromatography Methods 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- 238000005160 1H NMR spectroscopy Methods 0.000 description 56
- 239000012044 organic layer Substances 0.000 description 48
- 238000002953 preparative HPLC Methods 0.000 description 48
- 238000005481 NMR spectroscopy Methods 0.000 description 47
- 239000002904 solvent Substances 0.000 description 46
- 239000011734 sodium Substances 0.000 description 39
- 239000000460 chlorine Substances 0.000 description 37
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- 241000700721 Hepatitis B virus Species 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 35
- 0 CC(**=C)(C=*C=C*1C2)C1=*C=C2NC Chemical compound CC(**=C)(C=*C=C*1C2)C1=*C=C2NC 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 34
- 239000000706 filtrate Substances 0.000 description 30
- 239000012043 crude product Substances 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000000543 intermediate Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 239000000725 suspension Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 239000003826 tablet Substances 0.000 description 22
- 239000002775 capsule Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 239000012299 nitrogen atmosphere Substances 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 239000012065 filter cake Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 12
- 150000003857 carboxamides Chemical class 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000000707 stereoselective effect Effects 0.000 description 9
- 238000004808 supercritical fluid chromatography Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 8
- YQTMTTYLZOOAHH-UHFFFAOYSA-N 5-amino-3-bromo-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)Br)C(=O)NC1=CC(=C(C=C1)F)Cl YQTMTTYLZOOAHH-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical class CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 150000002430 hydrocarbons Chemical class 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 239000007821 HATU Substances 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 235000011056 potassium acetate Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 7
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
- KHGFALRALHLMOW-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one Chemical compound C1C2C=C(B3OC(C(C)(C)O3)(C)C)CC2CC1=O KHGFALRALHLMOW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 5
- 108020004638 Circular DNA Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- HAAOHBCJARVREN-UHFFFAOYSA-N cyclopenten-1-yl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CCCC1 HAAOHBCJARVREN-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 125000001207 fluorophenyl group Chemical group 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 238000007373 indentation Methods 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 238000012746 preparative thin layer chromatography Methods 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 4
- HRHZYWLKXOKRPU-UHFFFAOYSA-N 5-amino-3-(5-carbamoyl-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)C(N)=O)C(=O)NC1=CC(=C(C=C1)F)Cl HRHZYWLKXOKRPU-UHFFFAOYSA-N 0.000 description 4
- ZTRPGPYXFHQPIS-UHFFFAOYSA-N 5-amino-3-[5-(3-bromopropylsulfonylmethyl)-5-hydroxy-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O)CS(=O)(=O)CCCBr)C(=O)NC1=CC(=C(C=C1)F)Cl ZTRPGPYXFHQPIS-UHFFFAOYSA-N 0.000 description 4
- FJJWMNGBHMSDQA-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(3-phenylcyclobutyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC(C1)C1=CC=CC=C1)C(=O)NC1=CC(=C(C=C1)F)Cl FJJWMNGBHMSDQA-UHFFFAOYSA-N 0.000 description 4
- KWQJCDUICGUVNQ-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[3-(1-methylpyrazol-4-yl)cyclopentyl]pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C=1C=NN(C=1)C)C(=O)NC1=CC(=C(C=C1)F)Cl KWQJCDUICGUVNQ-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- COLVCKWALHUMBA-UHFFFAOYSA-N ethyl 5-amino-1-methyl-3-(3-phenylcyclobutyl)pyrazole-4-carboxylate Chemical compound NC1=C(C(=NN1C)C1CC(C1)C1=CC=CC=C1)C(=O)OCC COLVCKWALHUMBA-UHFFFAOYSA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 3
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- NFDGMTLLHGCGET-UHFFFAOYSA-N 2-[(2-bromoimidazol-1-yl)methoxy]ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCN1C=CN=C1Br NFDGMTLLHGCGET-UHFFFAOYSA-N 0.000 description 3
- DWPQYLOKFKKZRD-AWEZNQCLSA-N 2-[(3S)-3-(4-methoxyphenyl)cyclopenten-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound B1(OC(C(O1)(C)C)(C)C)C2=C[C@H](CC2)C3=CC=C(C=C3)OC DWPQYLOKFKKZRD-AWEZNQCLSA-N 0.000 description 3
- SBOHPSAMACKFSC-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)cyclopentan-1-one Chemical compound C1=NN(C)C=C1C1CC(=O)CC1 SBOHPSAMACKFSC-UHFFFAOYSA-N 0.000 description 3
- BCWXCAWSARGLMK-UHFFFAOYSA-N 3-amino-N-(3-chloro-4-fluorophenyl)-5-[5-hydroxy-5-(methylsulfonylmethyl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1H-pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1)C1CC2CC(CC2C1)(CS(=O)(=O)C)O)C(=O)NC1=CC(=C(C=C1)F)Cl BCWXCAWSARGLMK-UHFFFAOYSA-N 0.000 description 3
- CUMCJQNBSFAAAE-UHFFFAOYSA-N 3-phenylcyclobutane-1-carbonyl chloride Chemical compound ClC(=O)C1CC(C1)c1ccccc1 CUMCJQNBSFAAAE-UHFFFAOYSA-N 0.000 description 3
- TWVOWEDLLBJYSQ-UHFFFAOYSA-N 3-phenylcyclopentane-1-carbonitrile Chemical compound C1C(C#N)CCC1C1=CC=CC=C1 TWVOWEDLLBJYSQ-UHFFFAOYSA-N 0.000 description 3
- QJNHRKFUPJBGQE-UHFFFAOYSA-N 3-phenylcyclopentane-1-carboxamide Chemical compound C1(=CC=CC=C1)C1CC(CC1)C(=O)N QJNHRKFUPJBGQE-UHFFFAOYSA-N 0.000 description 3
- IWOLSKRVZNXDNU-UHFFFAOYSA-N 3-phenylcyclopentane-1-carboxylic acid Chemical compound C1C(C(=O)O)CCC1C1=CC=CC=C1 IWOLSKRVZNXDNU-UHFFFAOYSA-N 0.000 description 3
- FZKYKKMDZZRBFS-UHFFFAOYSA-N 3-pyridin-4-ylcyclopent-2-en-1-one Chemical compound O=C1CCC(C=2C=CN=CC=2)=C1 FZKYKKMDZZRBFS-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- DIVKMOHDPSXMDY-UHFFFAOYSA-N 5-amino-1-methyl-3-(3-phenylcyclopentyl)pyrazole-4-carbonyl chloride Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=CC=CC=C1)C(=O)Cl DIVKMOHDPSXMDY-UHFFFAOYSA-N 0.000 description 3
- SFXVLMFQZMBEHT-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(5-methylsulfanyl-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)SC)C(=O)NC1=CC(=C(C=C1)F)Cl SFXVLMFQZMBEHT-UHFFFAOYSA-N 0.000 description 3
- AMDRPEIIRRBNPU-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-(5-hydroxyimino-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)=NO)C(=O)NC1=CC(=C(C=C1)F)Cl AMDRPEIIRRBNPU-UHFFFAOYSA-N 0.000 description 3
- XSSPNRVZOJARHK-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-(5-methoxy-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)OC)C(=O)NC1=CC(=C(C=C1)F)Cl XSSPNRVZOJARHK-UHFFFAOYSA-N 0.000 description 3
- SWDCFNKYTMGWFP-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-hydroxy-5-(3-morpholin-4-ylpropylsulfonylmethyl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(CS(=O)(=O)CCCN1CCOCC1)O)C(=O)NC1=CC(=C(C=C1)F)Cl SWDCFNKYTMGWFP-UHFFFAOYSA-N 0.000 description 3
- QPDNAIQRFLNAAD-UHFFFAOYSA-N BrC1=C(C=C(C=C1)C=1N(C=CN=1)COCC[Si](C)(C)C)OC Chemical compound BrC1=C(C=C(C=C1)C=1N(C=CN=1)COCC[Si](C)(C)C)OC QPDNAIQRFLNAAD-UHFFFAOYSA-N 0.000 description 3
- YHWOUVBPHBWWHH-LSDHHAIUSA-N C1=C(C=CC(=C1)[C@H]1CC[C@@H](C2=NN(C(N)=C2C(=O)NC2=CC=C(C(=C2)Cl)F)C)C1)OC Chemical compound C1=C(C=CC(=C1)[C@H]1CC[C@@H](C2=NN(C(N)=C2C(=O)NC2=CC=C(C(=C2)Cl)F)C)C1)OC YHWOUVBPHBWWHH-LSDHHAIUSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- QDGZDCVAUDNJFG-FXQIFTODSA-N entecavir (anhydrous) Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- FJSVDVBINJVXGC-UHFFFAOYSA-N ethyl 3-amino-5-bromo-1H-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C(N)=NNC=1Br FJSVDVBINJVXGC-UHFFFAOYSA-N 0.000 description 3
- OSNNBWKIWOLWII-UHFFFAOYSA-N ethyl 5-amino-3-bromo-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)c1c(Br)nn(C)c1N OSNNBWKIWOLWII-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- ABHUUCTWDCSRMS-UHFFFAOYSA-N methyl 3-phenylcyclopentane-1-carboximidate hydrochloride Chemical compound Cl.C1(=CC=CC=C1)C1CC(CC1)C(OC)=N ABHUUCTWDCSRMS-UHFFFAOYSA-N 0.000 description 3
- JRRNVFZDCOUHFB-UHFFFAOYSA-N methyl 3-phenylcyclopentane-1-carboxylate Chemical compound C1C(C(=O)OC)CCC1C1=CC=CC=C1 JRRNVFZDCOUHFB-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- BXVGGHJBRCDSGU-JTQLQIEISA-N (3s)-3-(4-methoxyphenyl)cyclopentan-1-one Chemical compound C1=CC(OC)=CC=C1[C@@H]1CC(=O)CC1 BXVGGHJBRCDSGU-JTQLQIEISA-N 0.000 description 2
- LYPXTDXYEQEIIN-UHFFFAOYSA-N 1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NOC=1 LYPXTDXYEQEIIN-UHFFFAOYSA-N 0.000 description 2
- BTTUMVHWIAXYPJ-UHFFFAOYSA-N 1,3-dithian-2-yl(trimethyl)silane Chemical compound C[Si](C)(C)C1SCCCS1 BTTUMVHWIAXYPJ-UHFFFAOYSA-N 0.000 description 2
- JBRCMOPCVZJFEK-UHFFFAOYSA-N 1-methyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-yl]pyrazole Chemical compound B1(OC(C(O1)(C)C)(C)C)C2=CC(CC2)C3=CN(N=C3)C JBRCMOPCVZJFEK-UHFFFAOYSA-N 0.000 description 2
- JHAHAUYJIIKYIC-UHFFFAOYSA-N 1-methylpyrazole-4-carboxamide Chemical compound CN1C=C(C(N)=O)C=N1 JHAHAUYJIIKYIC-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XULLZEBEDJCZSG-UHFFFAOYSA-N 2-(3-phenylcyclopentylidene)-1,3-dithiane Chemical compound C1CSC(=C2CCC(C2)C3=CC=CC=C3)SC1 XULLZEBEDJCZSG-UHFFFAOYSA-N 0.000 description 2
- OTPKZQYVJORMOP-UHFFFAOYSA-N 2-(4-bromo-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C1=C(Br)C(OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 OTPKZQYVJORMOP-UHFFFAOYSA-N 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 2
- RZYYOTFJQUYWOC-UHFFFAOYSA-N 3-(1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl)-5-amino-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2C(CNC2)C1)C(=O)NC1=CC(=C(C=C1)F)Cl RZYYOTFJQUYWOC-UHFFFAOYSA-N 0.000 description 2
- IOWPNBPOZLLEQS-UHFFFAOYSA-N 3-(1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-5-amino-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CCCC2C1)C(=O)NC1=CC(=C(C=C1)F)Cl IOWPNBPOZLLEQS-UHFFFAOYSA-N 0.000 description 2
- LDDAHXOUNDKRSN-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)cyclopent-2-en-1-one Chemical compound C1=NN(C)C=C1C1=CC(=O)CC1 LDDAHXOUNDKRSN-UHFFFAOYSA-N 0.000 description 2
- MDVFUPOJJJSPOY-UHFFFAOYSA-N 3-(2-chlorophenyl)cyclopentan-1-one Chemical compound ClC1=CC=CC=C1C1CC(=O)CC1 MDVFUPOJJJSPOY-UHFFFAOYSA-N 0.000 description 2
- GFCZRWULMZZAJI-UHFFFAOYSA-N 3-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]thiophen-5-yl)-5-amino-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2C(CSC2)C1)C(=O)NC1=CC(=C(C=C1)F)Cl GFCZRWULMZZAJI-UHFFFAOYSA-N 0.000 description 2
- CGTGLMSBJLJNCL-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-one Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(=O)CC1 CGTGLMSBJLJNCL-UHFFFAOYSA-N 0.000 description 2
- BCHKGJUCTUHKCX-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]cyclopentan-1-one Chemical compound C1=CC(N(C)C)=CC=C1C1CC(=O)CC1 BCHKGJUCTUHKCX-UHFFFAOYSA-N 0.000 description 2
- VVENJDXCRIICMH-UHFFFAOYSA-N 3-amino-5-bromo-N-(3-chloro-4-fluorophenyl)-1H-pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1)Br)C(=O)NC1=CC(=C(C=C1)F)Cl VVENJDXCRIICMH-UHFFFAOYSA-N 0.000 description 2
- MYBDRXIXHHFTDR-UHFFFAOYSA-N 3-amino-N-(3-chloro-4-fluorophenyl)-5-(5-oxo-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl)-1H-pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1)C1CC2CC(CC2C1)=O)C(=O)NC1=CC(=C(C=C1)F)Cl MYBDRXIXHHFTDR-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WFWJGCQBMPIJKO-UHFFFAOYSA-N 4-[3-[5-amino-4-[(3-chloro-4-fluorophenyl)carbamoyl]-1-methylpyrazol-3-yl]cyclopentyl]-3-methoxybenzoic acid Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=C(C=C(C(=O)O)C=C1)OC)C(NC1=CC(=C(C=C1)F)Cl)=O WFWJGCQBMPIJKO-UHFFFAOYSA-N 0.000 description 2
- IXJSDKIJPVSPKF-UHFFFAOYSA-N 4-bromo-1-methylpyrazole Chemical compound CN1C=C(Br)C=N1 IXJSDKIJPVSPKF-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- VTKZQDWIRLQOLU-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one Chemical compound CN1N=CC(=C1)C1CC2CC(CC2C1)=O VTKZQDWIRLQOLU-UHFFFAOYSA-N 0.000 description 2
- CXYLWWJEEVXPIF-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one Chemical compound CN1N=CC(=C1)C1=CC2CC(CC2C1)=O CXYLWWJEEVXPIF-UHFFFAOYSA-N 0.000 description 2
- KCZFSJORKCGKOJ-UHFFFAOYSA-N 5-(1H-imidazol-5-yl)-3,3a,4,6a-tetrahydro-1H-pentalen-2-one Chemical compound N1C=NC(=C1)C1=CC2CC(CC2C1)=O KCZFSJORKCGKOJ-UHFFFAOYSA-N 0.000 description 2
- AJEHARPNDHWAAQ-UHFFFAOYSA-N 5-[5-amino-4-[(3-chloro-4-fluorophenyl)carbamoyl]-1-methylpyrazol-3-yl]-1,2,3,3a,4,5,6,6a-octahydropentalene-2-carboxylic acid Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)C(=O)O)C(NC1=CC(=C(C=C1)F)Cl)=O AJEHARPNDHWAAQ-UHFFFAOYSA-N 0.000 description 2
- LCTZVUDJGZAMQQ-UHFFFAOYSA-N 5-[5-amino-4-[(3-chloro-4-fluorophenyl)carbamoyl]-1-methylpyrazol-3-yl]-2-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-pentalene-2-carboxylic acid Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(C(=O)O)O)C(NC1=CC(=C(C=C1)F)Cl)=O LCTZVUDJGZAMQQ-UHFFFAOYSA-N 0.000 description 2
- BQGRERZGBYIOBB-UHFFFAOYSA-N 5-amino-1-methyl-3-(3-phenylcyclobutyl)pyrazole-4-carbonyl chloride Chemical compound NC1=C(C(=NN1C)C1CC(C1)C1=CC=CC=C1)C(=O)Cl BQGRERZGBYIOBB-UHFFFAOYSA-N 0.000 description 2
- GEMGLLKDFZPBNX-UHFFFAOYSA-N 5-amino-1-methyl-3-(3-phenylcyclobutyl)pyrazole-4-carboxylic acid Chemical compound NC1=C(C(=NN1C)C1CC(C1)C1=CC=CC=C1)C(=O)O GEMGLLKDFZPBNX-UHFFFAOYSA-N 0.000 description 2
- NFUSWEJXFWLAMU-UHFFFAOYSA-N 5-amino-3-(3-phenylcyclopentyl)-1,2-oxazole-4-carboxylic acid Chemical compound NC1=C(C(=NO1)C1CC(CC1)C1=CC=CC=C1)C(=O)O NFUSWEJXFWLAMU-UHFFFAOYSA-N 0.000 description 2
- WAADBVFEBIQZLG-UHFFFAOYSA-N 5-amino-3-(5-amino-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)N)C(=O)NC1=CC(=C(C=C1)F)Cl WAADBVFEBIQZLG-UHFFFAOYSA-N 0.000 description 2
- AXOFENDKUBPWLA-UHFFFAOYSA-N 5-amino-3-[5-(3-bromopropylsulfanylmethyl)-5-hydroxy-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O)CSCCCBr)C(=O)NC1=CC(=C(C=C1)F)Cl AXOFENDKUBPWLA-UHFFFAOYSA-N 0.000 description 2
- ITABUDUQUMVGQV-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(1-phenylpyrrolidin-3-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CN(CC1)C1=CC=CC=C1)C(=O)NC1=CC(=C(C=C1)F)Cl ITABUDUQUMVGQV-UHFFFAOYSA-N 0.000 description 2
- LNUVJOAWLZQOPC-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(2'-oxospiro[2,3,3a,4,6,6a-hexahydro-1H-pentalene-5,4'-pyrrolidine]-2-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC3(CNC(C3)=O)CC2C1)C(=O)NC1=CC(=C(C=C1)F)Cl LNUVJOAWLZQOPC-UHFFFAOYSA-N 0.000 description 2
- KNTAYHIDJXRORR-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(2-oxospiro[1,3-oxazolidine-5,5'-2,3,3a,4,6,6a-hexahydro-1H-pentalene]-2'-yl)pyrazole-4-carboxamide Chemical compound N1C(=O)OC2(CC3CC(C4=NN(C(N)=C4C(=O)NC4=CC=C(C(Cl)=C4)F)C)CC3C2)C1 KNTAYHIDJXRORR-UHFFFAOYSA-N 0.000 description 2
- XBZCOTVACSDISB-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(3-phenylcyclopentyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=CC=CC=C1)C(=O)NC1=CC(=C(C=C1)F)Cl XBZCOTVACSDISB-UHFFFAOYSA-N 0.000 description 2
- FIXWGHBFMZBQME-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(5-oxo-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)=O)C(=O)NC1=CC(=C(C=C1)F)Cl FIXWGHBFMZBQME-UHFFFAOYSA-N 0.000 description 2
- SBDFCBDXNJOLOZ-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(5-propan-2-yl-1,2,3,3a,4,6a-hexahydropentalen-2-yl)pyrazole-4-carboxamide Chemical compound CC(C1=CC2C(C1)CC(C1=NN(C(N)=C1C(=O)NC1=CC=C(C(=C1)Cl)F)C)C2)C SBDFCBDXNJOLOZ-UHFFFAOYSA-N 0.000 description 2
- DGMMVNQSHLCPLI-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[5-(methylamino)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)NC)C(=O)NC1=CC(=C(C=C1)F)Cl DGMMVNQSHLCPLI-UHFFFAOYSA-N 0.000 description 2
- IVLIYXOYFUYAGJ-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-spiro[1,3-dioxolane-2,5'-2,3,3a,4,6,6a-hexahydro-1H-pentalene]-2'-ylpyrazole-4-carboxamide Chemical compound C1OC2(OC1)CC1C(CC(C3=NN(C(=C3C(=O)NC3=CC=C(C(=C3)Cl)F)N)C)C1)C2 IVLIYXOYFUYAGJ-UHFFFAOYSA-N 0.000 description 2
- UYERQXDOOHYRIF-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-spiro[1,3-dithiolane-2,5'-2,3,3a,4,6,6a-hexahydro-1H-pentalene]-2'-ylpyrazole-4-carboxamide Chemical compound S1CCSC21CC1CC(C3=NN(C(=C3C(=O)NC3=CC(Cl)=C(F)C=C3)N)C)CC1C2 UYERQXDOOHYRIF-UHFFFAOYSA-N 0.000 description 2
- ZYPRTYZPMBUYMA-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-(5-hydroxy-5-propan-2-yl-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(C(C)C)O)C(=O)NC1=CC(=C(C=C1)F)Cl ZYPRTYZPMBUYMA-UHFFFAOYSA-N 0.000 description 2
- YHWOUVBPHBWWHH-HUUCEWRRSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[(1R,3R)-3-(4-methoxyphenyl)cyclopentyl]-1-methylpyrazole-4-carboxamide Chemical compound C1=C(C=CC(=C1)[C@@H]1CC[C@@H](C2=NN(C(=C2C(=O)NC2=CC=C(C(Cl)=C2)F)N)C)C1)OC YHWOUVBPHBWWHH-HUUCEWRRSA-N 0.000 description 2
- YHWOUVBPHBWWHH-CABCVRRESA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[(1S,3R)-3-(4-methoxyphenyl)cyclopentyl]-1-methylpyrazole-4-carboxamide Chemical compound C1=CC(=CC=C1[C@@H]1CC[C@@H](C1)C=1C(=C(N(N=1)C)N)C(=O)NC1=CC=C(C(Cl)=C1)F)OC YHWOUVBPHBWWHH-CABCVRRESA-N 0.000 description 2
- GMQQHFDMSAKCED-AWEZNQCLSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[(3S)-3-(4-methoxyphenyl)cyclopenten-1-yl]-1-methylpyrazole-4-carboxamide Chemical compound C1=C(C=CC([C@H]2CCC(=C2)C2=NN(C(N)=C2C(=O)NC2=CC(Cl)=C(F)C=C2)C)=C1)OC GMQQHFDMSAKCED-AWEZNQCLSA-N 0.000 description 2
- FIXRVHRRTKVHMK-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-(1H-imidazol-5-yl)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound N1C=NC(=C1)C1CC2CC(CC2C1)C1=NN(C(=C1C(=O)NC1=CC(=C(C=C1)F)Cl)N)C FIXRVHRRTKVHMK-UHFFFAOYSA-N 0.000 description 2
- MPPHZRLGFVAUOF-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-hydroxy-5-(2-hydroxypropan-2-yl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(C(C)(C)O)O)C(=O)NC1=CC(=C(C=C1)F)Cl MPPHZRLGFVAUOF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- QUWKHBPAKIDKPR-UHFFFAOYSA-N CC(C)(C)OC(N1C=NC(C2=CC(CC(C3)=O)C3C2)=C1)=O Chemical compound CC(C)(C)OC(N1C=NC(C2=CC(CC(C3)=O)C3C2)=C1)=O QUWKHBPAKIDKPR-UHFFFAOYSA-N 0.000 description 2
- ZEPILUDYYFSOHI-UHFFFAOYSA-N COC1=C(C=CC(=C1)C=1N(C=CN=1)COCC[Si](C)(C)C)C1=CC(CC1)=O Chemical compound COC1=C(C=CC(=C1)C=1N(C=CN=1)COCC[Si](C)(C)C)C1=CC(CC1)=O ZEPILUDYYFSOHI-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229940122806 Cyclophilin inhibitor Drugs 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- UHBJCJOHKSEBFJ-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-1-methyl-3-(5-oxo-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl)pyrazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C=1C(=NN(C=1)C)C1CC2CC(CC2C1)=O UHBJCJOHKSEBFJ-UHFFFAOYSA-N 0.000 description 2
- ZQOCHUGDQKQKQU-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-3-[5-hydroxy-5-(methylsulfonylmethyl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound ClC=1C=C(C=CC=1F)NC(=O)C=1C(=NN(C=1)C)C1CC2CC(CC2C1)(CS(=O)(=O)C)O ZQOCHUGDQKQKQU-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- UHSGLEWJFHOSHA-UHFFFAOYSA-N NC1=C(C(=NN1C)C1CC2CC(CC2C1)N(C)C)C(=O)NC1=CC(=C(C=C1)F)Cl Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)N(C)C)C(=O)NC1=CC(=C(C=C1)F)Cl UHSGLEWJFHOSHA-UHFFFAOYSA-N 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- JPHHEXLTYUIRTI-UHFFFAOYSA-N O=C1CC2CC(CC2C1)C=1N=CN(C=1)C(=O)OC(C)(C)C Chemical compound O=C1CC2CC(CC2C1)C=1N=CN(C=1)C(=O)OC(C)(C)C JPHHEXLTYUIRTI-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940044665 STING agonist Drugs 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010078233 Thymalfasin Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940045348 brown mixture Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 239000000134 cyclophilin inhibitor Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960000980 entecavir Drugs 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- HGVNIRYMFIJLJQ-UHFFFAOYSA-N methyl 3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1B1OC(C)(C)C(C)(C)O1 HGVNIRYMFIJLJQ-UHFFFAOYSA-N 0.000 description 2
- WJDFFFAQQPXERR-UHFFFAOYSA-N methyl 4-[3-[5-amino-4-[(3-chloro-4-fluorophenyl)carbamoyl]-1-methylpyrazol-3-yl]cyclopentyl]-3-methoxybenzoate Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=C(C=C(C(=O)OC)C=C1)OC)C(NC1=CC(=C(C=C1)F)Cl)=O WJDFFFAQQPXERR-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 229940075439 smac mimetic Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- 229960004556 tenofovir Drugs 0.000 description 2
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 description 2
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
- PTUXVACHNRAHTJ-UHFFFAOYSA-N tert-butyl 5-(trifluoromethylsulfonyloxy)-3,3a,6,6a-tetrahydro-1h-cyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(OS(=O)(=O)C(F)(F)F)=CC2CN(C(=O)OC(C)(C)C)CC21 PTUXVACHNRAHTJ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 1
- NQMRYYAAICMHPE-UHFFFAOYSA-N (4-methoxyphenyl)boron Chemical compound [B]C1=CC=C(OC)C=C1 NQMRYYAAICMHPE-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RNRUVKDGYUVWCV-MRXNPFEDSA-N (R)-2-methyl-N-(3-phenylprop-2-enyl)propane-2-sulfinamide Chemical compound C(C)(C)(C)[S@@](=O)NCC=CC1=CC=CC=C1 RNRUVKDGYUVWCV-MRXNPFEDSA-N 0.000 description 1
- 108010030583 (melle-4)cyclosporin Proteins 0.000 description 1
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- IVXVPIOWIKLBGN-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalen-2-amine Chemical compound C1CCC2CC(N)CC21 IVXVPIOWIKLBGN-UHFFFAOYSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- BNFRVTFSKSRGHM-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene-2-carboxylic acid Chemical compound C1CCC2CC(C(=O)O)CC21 BNFRVTFSKSRGHM-UHFFFAOYSA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- QBPXGTUBZXXKJO-UHFFFAOYSA-N 1,2-oxazole-4-carboxamide Chemical compound NC(=O)C=1C=NOC=1 QBPXGTUBZXXKJO-UHFFFAOYSA-N 0.000 description 1
- WGUHSXWRJNEGPK-UHFFFAOYSA-N 1,3,3a,4,6,6a-hexahydrocyclopenta[c]thiophen-5-one Chemical compound C1SCC2CC(=O)CC21 WGUHSXWRJNEGPK-UHFFFAOYSA-N 0.000 description 1
- HAFQHNGZPQYKFF-UHFFFAOYSA-N 1,3,3a,4,6,6a-hexahydropentalene-2,5-dione Chemical compound C1C(=O)CC2CC(=O)CC21 HAFQHNGZPQYKFF-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
- XHEOXSQMBWJOKP-UHFFFAOYSA-N 1-(trifluoromethyl)-1$l^{3},2-benziodoxol-3-one Chemical compound C1=CC=C2I(C(F)(F)F)OC(=O)C2=C1 XHEOXSQMBWJOKP-UHFFFAOYSA-N 0.000 description 1
- PIPWNWZBTWYPJB-UHFFFAOYSA-N 1-bromo-4-iodo-2-methoxybenzene Chemical compound COC1=CC(I)=CC=C1Br PIPWNWZBTWYPJB-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- NANCCEWFYNTLFX-UHFFFAOYSA-N 1h-pentalen-2-one Chemical compound C1=CC2=CC(=O)CC2=C1 NANCCEWFYNTLFX-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- VSMIXBPXQCUVRO-UHFFFAOYSA-N 2-(3,3a,6,6a-tetrahydro-1H-cyclopenta[c]thiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound B1(OC(C(O1)(C)C)(C)C)C2=CC3CSCC3C2 VSMIXBPXQCUVRO-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- OQBKQYGAMDDBKR-UHFFFAOYSA-N 2-[5-[5-amino-4-[(3-chloro-4-fluorophenyl)carbamoyl]-1-methylpyrazol-3-yl]-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]acetic acid Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)CC(=O)O)C(NC1=CC(=C(C=C1)F)Cl)=O OQBKQYGAMDDBKR-UHFFFAOYSA-N 0.000 description 1
- AXHRGVJWDJDYPO-UHFFFAOYSA-N 2-bromo-1h-imidazole Chemical compound BrC1=NC=CN1 AXHRGVJWDJDYPO-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OGBZELSUKYODHJ-UHFFFAOYSA-N 2-tert-butyl-4-methylpyridine Chemical compound CC1=CC=NC(C(C)(C)C)=C1 OGBZELSUKYODHJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GTVUGPOLOIQVEI-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-2-carboxylic acid Chemical compound C1CCC2CN(C(=O)O)CC21 GTVUGPOLOIQVEI-UHFFFAOYSA-N 0.000 description 1
- FRBSBIJFICEHGL-UHFFFAOYSA-N 3,3a,4,5-tetrahydro-1H-pentalen-2-one Chemical compound C1CC=C2CC(=O)CC21 FRBSBIJFICEHGL-UHFFFAOYSA-N 0.000 description 1
- KXHPHWXSBTXYRZ-UHFFFAOYSA-N 3,3a,6,6a-tetrahydro-1H-cyclopenta[c]thiophen-5-yl trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OC=1CC2C(CSC2)C=1)(F)F KXHPHWXSBTXYRZ-UHFFFAOYSA-N 0.000 description 1
- KLRMVIQFROFWDU-UHFFFAOYSA-N 3-(2-acetyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl)-5-amino-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound C(C)(=O)N1CC2C(C1)CC(C2)C1=NN(C(=C1C(=O)NC1=CC(=C(C=C1)F)Cl)N)C KLRMVIQFROFWDU-UHFFFAOYSA-N 0.000 description 1
- IYINCXYFJZVKEM-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]cyclopent-2-en-1-one Chemical compound C1=CC(N(C)C)=CC=C1C1=CC(=O)CC1 IYINCXYFJZVKEM-UHFFFAOYSA-N 0.000 description 1
- IJICWGIJUIDTRP-UHFFFAOYSA-N 3-amino-N-(3-chloro-4-fluorophenyl)-5-(5-oxo-3a,4,6,6a-tetrahydro-1H-pentalen-2-yl)-1H-pyrazole-4-carboxamide Chemical compound C1C(=CC2CC(=O)CC12)C1=NNC(N)=C1C(=O)NC1=CC=C(C(=C1)Cl)F IJICWGIJUIDTRP-UHFFFAOYSA-N 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical class C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- GYPOUGZGHDSUKH-UHFFFAOYSA-N 3-bromo-4,5-difluoroaniline Chemical compound NC1=CC(F)=C(F)C(Br)=C1 GYPOUGZGHDSUKH-UHFFFAOYSA-N 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- KOSJHQBPJQYNTB-UHFFFAOYSA-N 3-phenylcyclobutane-1-carboxylic acid Chemical compound C1C(C(=O)O)CC1C1=CC=CC=C1 KOSJHQBPJQYNTB-UHFFFAOYSA-N 0.000 description 1
- MFBXYJLOYZMFIN-UHFFFAOYSA-N 3-phenylcyclopentan-1-one Chemical compound C1C(=O)CCC1C1=CC=CC=C1 MFBXYJLOYZMFIN-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- MKOIWLVTFRQTJW-UHFFFAOYSA-N 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine Chemical compound C1CCCN2C=NN=C21 MKOIWLVTFRQTJW-UHFFFAOYSA-N 0.000 description 1
- BBLXLHYPDOMJMO-UHFFFAOYSA-N 5-(butan-2-ylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound CCC(C)NS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 BBLXLHYPDOMJMO-UHFFFAOYSA-N 0.000 description 1
- VRGVJZJFGBSHFY-UHFFFAOYSA-N 5-amino-1-methyl-3-(3-phenylcyclopentyl)pyrazole-4-carboxylic acid Chemical compound CN1C(=C(C(=N1)C2CCC(C2)C3=CC=CC=C3)C(=O)O)N VRGVJZJFGBSHFY-UHFFFAOYSA-N 0.000 description 1
- XZVAMWUZQLNAJW-UHFFFAOYSA-N 5-amino-3-[3-(4-carbamoyl-2-methoxyphenyl)cyclopentyl]-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=C(C=C(C=C1)C(N)=O)OC)C(=O)NC1=CC(=C(C=C1)F)Cl XZVAMWUZQLNAJW-UHFFFAOYSA-N 0.000 description 1
- OOLVDQPBNNRAEK-UHFFFAOYSA-N 5-amino-3-[5-(2-amino-2-oxoethyl)-5-hydroxy-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O)CC(=O)N)C(=O)NC1=CC(=C(C=C1)F)Cl OOLVDQPBNNRAEK-UHFFFAOYSA-N 0.000 description 1
- UNIMEDMZIVXWGF-UHFFFAOYSA-N 5-amino-3-[5-(aminomethyl)-5-hydroxy-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-N-(3-chloro-4-fluorophenyl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O)CN)C(=O)NC1=CC(=C(C=C1)F)Cl UNIMEDMZIVXWGF-UHFFFAOYSA-N 0.000 description 1
- BLMBOPIJDLLCFE-UHFFFAOYSA-N 5-amino-N-(3-bromo-4,5-difluorophenyl)-1-methyl-3-(3-phenylcyclopentyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=CC=CC=C1)C(=O)NC1=CC(=C(C(=C1)F)F)Br BLMBOPIJDLLCFE-UHFFFAOYSA-N 0.000 description 1
- IARGUKWIBCWMMO-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(3-oxo-4,4a,5,6,7,7a-hexahydro-1H-cyclopenta[c]pyran-6-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2C(COC(C2)=O)C1)C(=O)NC1=CC(=C(C=C1)F)Cl IARGUKWIBCWMMO-UHFFFAOYSA-N 0.000 description 1
- YHUDTGQOCLIUEN-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(3-phenylcyclopenten-1-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1=CC(CC1)C1=CC=CC=C1)C(=O)NC1=CC(=C(C=C1)F)Cl YHUDTGQOCLIUEN-UHFFFAOYSA-N 0.000 description 1
- IFQYXGCZNRXCOE-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(5-methylsulfinyl-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)pyrazole-4-carboxamide Chemical compound S(=O)(C1CC2CC(C3=NN(C(=C3C(=O)NC3=CC(Cl)=C(F)C=C3)N)C)CC2C1)C IFQYXGCZNRXCOE-UHFFFAOYSA-N 0.000 description 1
- DVHXNWZABPPZII-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-(5-oxo-3a,4,6,6a-tetrahydro-1H-pentalen-2-yl)pyrazole-4-carboxamide Chemical compound C1(=O)CC2CC(=CC2C1)C1=NN(C(N)=C1C(=O)NC1=CC=C(C(=C1)Cl)F)C DVHXNWZABPPZII-UHFFFAOYSA-N 0.000 description 1
- WQEJFDDHLQHVCB-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[3-(1-methylpyrazol-4-yl)cyclopenten-1-yl]pyrazole-4-carboxamide Chemical class NC1=C(C(=NN1C)C1=CC(CC1)C=1C=NN(C=1)C)C(=O)NC1=CC(=C(C=C1)F)Cl WQEJFDDHLQHVCB-UHFFFAOYSA-N 0.000 description 1
- ILRAYGCIJATMJX-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[5-(1-methylpyrazol-4-yl)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)C=1C=NN(C=1)C)C(=O)NC1=CC(=C(C=C1)F)Cl ILRAYGCIJATMJX-UHFFFAOYSA-N 0.000 description 1
- CRPMJNDKJGWDBC-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[5-(2-oxo-1,3-oxazolidin-3-yl)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)N1C(OCC1)=O)C(=O)NC1=CC(=C(C=C1)F)Cl CRPMJNDKJGWDBC-UHFFFAOYSA-N 0.000 description 1
- SKRLQMHVPAGUGI-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[5-(2-oxoimidazolidin-1-yl)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)N1C(NCC1)=O)C(=O)NC1=CC(=C(C=C1)F)Cl SKRLQMHVPAGUGI-UHFFFAOYSA-N 0.000 description 1
- KIXBZDDUEUQBSD-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-[5-(trifluoromethoxy)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)OC(F)(F)F)C(=O)NC1=CC(=C(C=C1)F)Cl KIXBZDDUEUQBSD-UHFFFAOYSA-N 0.000 description 1
- IOHISAZFQWBJDQ-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-1-methyl-3-pyrrolidin-3-ylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CNCC1)C(=O)NC1=CC(=C(C=C1)F)Cl IOHISAZFQWBJDQ-UHFFFAOYSA-N 0.000 description 1
- IDYITMHDKYFDTJ-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-(2-ethylspiro[1,3-dioxolane-4,5'-2,3,3a,4,6,6a-hexahydro-1H-pentalene]-2'-yl)-1-methylpyrazole-4-carboxamide Chemical compound C1(OCC2(O1)CC1C(CC(C3=NN(C(N)=C3C(=O)NC3=CC(Cl)=C(F)C=C3)C)C1)C2)CC IDYITMHDKYFDTJ-UHFFFAOYSA-N 0.000 description 1
- CRPUJFPVOMYIDY-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-(5-cyano-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)C#N)C(=O)NC1=CC(=C(C=C1)F)Cl CRPUJFPVOMYIDY-UHFFFAOYSA-N 0.000 description 1
- SVQRHLLYDXEODS-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-(5-hydroxy-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl)-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)O)C(=O)NC1=CC(=C(C=C1)F)Cl SVQRHLLYDXEODS-UHFFFAOYSA-N 0.000 description 1
- YHWOUVBPHBWWHH-GJZGRUSLSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[(1S,3S)-3-(4-methoxyphenyl)cyclopentyl]-1-methylpyrazole-4-carboxamide Chemical compound C1=C(C=CC(=C1)[C@H]1CC[C@@H](C1)C=1C(=C(N(N=1)C)N)C(=O)NC1=CC=C(C(=C1)Cl)F)OC YHWOUVBPHBWWHH-GJZGRUSLSA-N 0.000 description 1
- OMWYYYQYVGASSX-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[3-[4-(1H-imidazol-2-yl)-2-methoxyphenyl]cyclopentyl]-1-methylpyrazole-4-carboxamide Chemical compound N1C(=NC=C1)C1=CC(=C(C=C1)C1CC(CC1)C1=NN(C(=C1C(=O)NC1=CC(=C(C=C1)F)Cl)N)C)OC OMWYYYQYVGASSX-UHFFFAOYSA-N 0.000 description 1
- BTRLXMIWPGMXDE-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-(2-hydroxyethyl)-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)CCO)C(=O)NC1=CC(=C(C=C1)F)Cl BTRLXMIWPGMXDE-UHFFFAOYSA-N 0.000 description 1
- BFTGUIHZPBCULC-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-(difluoromethoxymethyl)-5-hydroxy-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O)COC(F)F)C(=O)NC1=CC(=C(C=C1)F)Cl BFTGUIHZPBCULC-UHFFFAOYSA-N 0.000 description 1
- ILXZOKQPLAQBHK-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-hydroxy-5-(2-methylsulfonylethyl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(CCS(=O)(=O)C)O)C(=O)NC1=CC(=C(C=C1)F)Cl ILXZOKQPLAQBHK-UHFFFAOYSA-N 0.000 description 1
- ORPPJRIAUMMMJR-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-hydroxy-5-(methylsulfanylmethyl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(CSC)O)C(=O)NC1=CC(=C(C=C1)F)Cl ORPPJRIAUMMMJR-UHFFFAOYSA-N 0.000 description 1
- PGLBCTPMUFVCJI-UHFFFAOYSA-N 5-amino-N-(3-chloro-4-fluorophenyl)-3-[5-hydroxy-5-(propan-2-yloxymethyl)-2,3,3a,4,6,6a-hexahydro-1H-pentalen-2-yl]-1-methylpyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(COC(C)C)O)C(=O)NC1=CC(=C(C=C1)F)Cl PGLBCTPMUFVCJI-UHFFFAOYSA-N 0.000 description 1
- PDTSGULTKPCGNF-UHFFFAOYSA-N 5-amino-N-(3-cyano-4-fluorophenyl)-1-methyl-3-(3-phenylcyclopentyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=CC=CC=C1)C(=O)NC1=CC(=C(C=C1)F)C#N PDTSGULTKPCGNF-UHFFFAOYSA-N 0.000 description 1
- FHZALEJIENDROK-UHFFFAOYSA-N 5-bromo-1h-imidazole Chemical compound BrC1=CN=CN1 FHZALEJIENDROK-UHFFFAOYSA-N 0.000 description 1
- XHZWFUVEKDDQPF-UHFFFAOYSA-N 5-bromo-1h-pyrazole Chemical compound BrC1=CC=NN1 XHZWFUVEKDDQPF-UHFFFAOYSA-N 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- FXCXNYOEQRAMPJ-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1CCCCC2=NN=CN21 FXCXNYOEQRAMPJ-UHFFFAOYSA-N 0.000 description 1
- MEUPFNYFCRQDMK-UHFFFAOYSA-N 6,9-dihydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1C=CCCN2C=NN=C21 MEUPFNYFCRQDMK-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MGJSAPCKYOKRQB-UHFFFAOYSA-N 8,9-dihydro-5H-[1,2,4]triazolo[4,3-a]azepine Chemical compound N=1N=CN2C=1CCC=CC2 MGJSAPCKYOKRQB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- PKWRMUKBEYJEIX-DXXQBUJASA-N Birinapant Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OBVGLLOYAQUDKB-JYRVWZFOSA-N CC(C)(C)OC(N(/C=C(/C(C1)CC(C2)C1CC2=O)\N)S)=O Chemical compound CC(C)(C)OC(N(/C=C(/C(C1)CC(C2)C1CC2=O)\N)S)=O OBVGLLOYAQUDKB-JYRVWZFOSA-N 0.000 description 1
- SBTMLYVNIFZHIO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1C2)CC1C=C2c1n[n](C)c(N)c1C(Nc(cc1Cl)ccc1F)=O)=O Chemical compound CC(C)(C)OC(N(CC1C2)CC1C=C2c1n[n](C)c(N)c1C(Nc(cc1Cl)ccc1F)=O)=O SBTMLYVNIFZHIO-UHFFFAOYSA-N 0.000 description 1
- AVBWARCKGQCXSY-UHFFFAOYSA-N CC(C)(C)OC(Nc1c(C(Nc(cc2)cc(Cl)c2F)=O)c(C(C2)CC(C3)C2CC3(CS(C)(=O)=O)O)n[nH]1)=O Chemical compound CC(C)(C)OC(Nc1c(C(Nc(cc2)cc(Cl)c2F)=O)c(C(C2)CC(C3)C2CC3(CS(C)(=O)=O)O)n[nH]1)=O AVBWARCKGQCXSY-UHFFFAOYSA-N 0.000 description 1
- RNRUVKDGYUVWCV-INIZCTEOSA-N CC(C)(C)[S@@](NCC=CC1=CC=CC=C1)=O Chemical compound CC(C)(C)[S@@](NCC=CC1=CC=CC=C1)=O RNRUVKDGYUVWCV-INIZCTEOSA-N 0.000 description 1
- NRRZGMWSULMYOU-UHFFFAOYSA-N CC(C)(CCN1C)CS1(=O)=O Chemical compound CC(C)(CCN1C)CS1(=O)=O NRRZGMWSULMYOU-UHFFFAOYSA-N 0.000 description 1
- OOBDRRXUJGDZRJ-UHFFFAOYSA-N CC(NC1CC(CC(C2)c3n[n](C)c(N)c3C(Nc(cc3Cl)ccc3F)=O)C2C1)=O Chemical compound CC(NC1CC(CC(C2)c3n[n](C)c(N)c3C(Nc(cc3Cl)ccc3F)=O)C2C1)=O OOBDRRXUJGDZRJ-UHFFFAOYSA-N 0.000 description 1
- CWHCTKAJYQOXMG-UHFFFAOYSA-N CC1(C)CCN(C)CC1 Chemical compound CC1(C)CCN(C)CC1 CWHCTKAJYQOXMG-UHFFFAOYSA-N 0.000 description 1
- DGFSUDKBJWNNDJ-UHFFFAOYSA-N CCCN1CNC(C)(C)CC1 Chemical compound CCCN1CNC(C)(C)CC1 DGFSUDKBJWNNDJ-UHFFFAOYSA-N 0.000 description 1
- WSCGMOBBVZURIF-UHFFFAOYSA-N CCOC(C=C1CC(CC(C2)c3n[n](C)c(N)c3C(Nc(cc3)cc(Cl)c3F)=O)C2C1)=O Chemical compound CCOC(C=C1CC(CC(C2)c3n[n](C)c(N)c3C(Nc(cc3)cc(Cl)c3F)=O)C2C1)=O WSCGMOBBVZURIF-UHFFFAOYSA-N 0.000 description 1
- XHHNUNRKWKYVOM-UHFFFAOYSA-N CN(C1N)N=C(C(C2)CC(C3)C2CC3N(CCN2)C2=O)C1C(Nc(cc1)cc(Cl)c1F)=O Chemical compound CN(C1N)N=C(C(C2)CC(C3)C2CC3N(CCN2)C2=O)C1C(Nc(cc1)cc(Cl)c1F)=O XHHNUNRKWKYVOM-UHFFFAOYSA-N 0.000 description 1
- ILKMLMGHMJETTB-UHFFFAOYSA-N CN(C1N)N=C(C(C2)CC3C2CNC3)C1C(Nc(cc1Cl)ccc1F)=O Chemical compound CN(C1N)N=C(C(C2)CC3C2CNC3)C1C(Nc(cc1Cl)ccc1F)=O ILKMLMGHMJETTB-UHFFFAOYSA-N 0.000 description 1
- AYVDQORKOKQUSK-UHFFFAOYSA-N CN1NC(C(C2)CC2c2ccccc2)C(C(Cl)=O)=C1N Chemical compound CN1NC(C(C2)CC2c2ccccc2)C(C(Cl)=O)=C1N AYVDQORKOKQUSK-UHFFFAOYSA-N 0.000 description 1
- AUJWQTVWPIPRMJ-UHFFFAOYSA-N CNc1c(C(Nc(cc2)cc(Cl)c2F)=O)c(C(C2)CC(C3)C2CC3O)n[n]1C Chemical compound CNc1c(C(Nc(cc2)cc(Cl)c2F)=O)c(C(C2)CC(C3)C2CC3O)n[n]1C AUJWQTVWPIPRMJ-UHFFFAOYSA-N 0.000 description 1
- BJIAMLQBICRMII-UHFFFAOYSA-N COC(c1ccc(C(CC2)=CC2=O)c(OC)c1)=O Chemical compound COC(c1ccc(C(CC2)=CC2=O)c(OC)c1)=O BJIAMLQBICRMII-UHFFFAOYSA-N 0.000 description 1
- PBIBIRGMZPIFSW-UHFFFAOYSA-N C[n]1nc(C(C2)=CC3C2CSC3)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N Chemical compound C[n]1nc(C(C2)=CC3C2CSC3)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N PBIBIRGMZPIFSW-UHFFFAOYSA-N 0.000 description 1
- CMIXVSTZFATZGJ-UHFFFAOYSA-N C[n]1nc(C(C2)CC(C3)C2CC3(C(NC2CC2)=O)O)c(C(Nc(cc2Cl)ccc2F)=O)c1N Chemical compound C[n]1nc(C(C2)CC(C3)C2CC3(C(NC2CC2)=O)O)c(C(Nc(cc2Cl)ccc2F)=O)c1N CMIXVSTZFATZGJ-UHFFFAOYSA-N 0.000 description 1
- KLLAERVJKZKTTM-UHFFFAOYSA-N C[n]1nc(C(C2)CC(C3)C2CC3=C2SCCCS2)c(C(Nc(cc2Cl)ccc2F)=O)c1N Chemical compound C[n]1nc(C(C2)CC(C3)C2CC3=C2SCCCS2)c(C(Nc(cc2Cl)ccc2F)=O)c1N KLLAERVJKZKTTM-UHFFFAOYSA-N 0.000 description 1
- JPJHMZRSRITBIH-UHFFFAOYSA-N C[n]1nc(C(C2)CC(C3)C2CC3OS(C)(=O)=O)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N Chemical compound C[n]1nc(C(C2)CC(C3)C2CC3OS(C)(=O)=O)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N JPJHMZRSRITBIH-UHFFFAOYSA-N 0.000 description 1
- SNAZWPXKTJPHAC-UHFFFAOYSA-N C[n]1nc(C(C2)CC(CN3)C2CC3=O)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N Chemical compound C[n]1nc(C(C2)CC(CN3)C2CC3=O)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N SNAZWPXKTJPHAC-UHFFFAOYSA-N 0.000 description 1
- DQJXAAXRXPAMBP-UHFFFAOYSA-N C[n]1nc(C2CC(CC(C3)C(OC)=O)C3C2)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N Chemical compound C[n]1nc(C2CC(CC(C3)C(OC)=O)C3C2)c(C(Nc(cc2)cc(Cl)c2F)=O)c1N DQJXAAXRXPAMBP-UHFFFAOYSA-N 0.000 description 1
- FSWKAXVBQRIOOG-HNNXBMFYSA-N C[n]1nc([C@@H](CC2)C=C2c(cc2)ccc2OC)c(C(Nc(cc2Cl)ccc2F)=O)c1N Chemical compound C[n]1nc([C@@H](CC2)C=C2c(cc2)ccc2OC)c(C(Nc(cc2Cl)ccc2F)=O)c1N FSWKAXVBQRIOOG-HNNXBMFYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- IKNQPNLSEBWZKX-UHFFFAOYSA-N Cc(cc1)cc(Cl)c1F Chemical compound Cc(cc1)cc(Cl)c1F IKNQPNLSEBWZKX-UHFFFAOYSA-N 0.000 description 1
- IMCULDWFDHJIPO-UHFFFAOYSA-N Cc1nc2cc(NC(c(cc3)ccc3S(N(C)Cc3ccccc3)(=O)=O)=O)ccc2[s]1 Chemical compound Cc1nc2cc(NC(c(cc3)ccc3S(N(C)Cc3ccccc3)(=O)=O)=O)ccc2[s]1 IMCULDWFDHJIPO-UHFFFAOYSA-N 0.000 description 1
- 108091036055 CccDNA Proteins 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 102100027704 Histone-lysine N-methyltransferase SETD7 Human genes 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101000650682 Homo sapiens Histone-lysine N-methyltransferase SETD7 Proteins 0.000 description 1
- 102100039384 Huntingtin-associated protein 1 Human genes 0.000 description 1
- 101710140977 Huntingtin-associated protein 1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229940083346 IAP antagonist Drugs 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- AEKNPGMERVKQDR-UHFFFAOYSA-N N1N=CC(=C1)C1CC2CC(CC2C1)C1=NN(C(=C1C(=O)NC1=CC(=C(C=C1)F)Cl)N)C Chemical compound N1N=CC(=C1)C1CC2CC(CC2C1)C1=NN(C(=C1C(=O)NC1=CC(=C(C=C1)F)Cl)N)C AEKNPGMERVKQDR-UHFFFAOYSA-N 0.000 description 1
- MOKRSKIGOHZQTR-UHFFFAOYSA-N NC1=C(C(=NN1C)C1CC(CC1)C1=C(C=C(C=C1)C#N)OC)C(=O)NC1=CC(=C(C=C1)F)Cl Chemical compound NC1=C(C(=NN1C)C1CC(CC1)C1=C(C=C(C=C1)C#N)OC)C(=O)NC1=CC(=C(C=C1)F)Cl MOKRSKIGOHZQTR-UHFFFAOYSA-N 0.000 description 1
- TWYMUHMXYOADCF-UHFFFAOYSA-N NC1=C(C(=NN1C)C1CC2CC(C(C2C1)O)(C(C)C)O)C(=O)NC1=CC(=C(C=C1)F)Cl Chemical compound NC1=C(C(=NN1C)C1CC2CC(C(C2C1)O)(C(C)C)O)C(=O)NC1=CC(=C(C=C1)F)Cl TWYMUHMXYOADCF-UHFFFAOYSA-N 0.000 description 1
- DSLIQUOZHONDBJ-UHFFFAOYSA-N NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O[Si](C)(C)C)C#N)C(=O)NC1=CC(=C(C=C1)F)Cl Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)(O[Si](C)(C)C)C#N)C(=O)NC1=CC(=C(C=C1)F)Cl DSLIQUOZHONDBJ-UHFFFAOYSA-N 0.000 description 1
- UCEJQGMNGDNWLJ-UHFFFAOYSA-N NC1=C(C(=NN1C)C1CC2CC(CC2C1)S(=O)(=O)C)C(=O)NC1=CC(=C(C=C1)F)Cl Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)S(=O)(=O)C)C(=O)NC1=CC(=C(C=C1)F)Cl UCEJQGMNGDNWLJ-UHFFFAOYSA-N 0.000 description 1
- RNRCRFDYQOLZES-ROUUACIJSA-N NC1=C(C(=NN1C)[C@@H]1C[C@H](CC1)C1=CC=C(C=C1)C=1N=CN(C=1)C)C(=O)NC1=CC(=C(C=C1)F)Cl Chemical compound NC1=C(C(=NN1C)[C@@H]1C[C@H](CC1)C1=CC=C(C=C1)C=1N=CN(C=1)C)C(=O)NC1=CC(=C(C=C1)F)Cl RNRCRFDYQOLZES-ROUUACIJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- ZRYKHZXSPWBXAO-UHFFFAOYSA-N Nc1c(C(NC(CC=C2F)C=C2Cl)=O)c(C2=CC(CC(C3)=O)C3C2)n[nH]1 Chemical compound Nc1c(C(NC(CC=C2F)C=C2Cl)=O)c(C2=CC(CC(C3)=O)C3C2)n[nH]1 ZRYKHZXSPWBXAO-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JKZSHWDPOQYSJW-UHFFFAOYSA-N O=C(CN(c(cc(C(F)(F)F)cc1)c1Cl)S(c1ccccc1)(=O)=O)NCc1ccncc1 Chemical compound O=C(CN(c(cc(C(F)(F)F)cc1)c1Cl)S(c1ccccc1)(=O)=O)NCc1ccncc1 JKZSHWDPOQYSJW-UHFFFAOYSA-N 0.000 description 1
- HBIRLKKYXKFKMI-UHFFFAOYSA-N OC(C1)=CC2C1CNC2 Chemical compound OC(C1)=CC2C1CNC2 HBIRLKKYXKFKMI-UHFFFAOYSA-N 0.000 description 1
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010090287 SCY-635 Proteins 0.000 description 1
- 101000615178 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Serine/threonine-protein kinase SKY1 Proteins 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- GFCJPYIRDNIEHR-UHFFFAOYSA-N [1,2,4]triazolo[4,3-d][1,4]oxazepine Chemical compound O1C=Cc2nncn2C=C1 GFCJPYIRDNIEHR-UHFFFAOYSA-N 0.000 description 1
- WDZVWBWAUSUTTO-UHFFFAOYSA-N [bromo(difluoro)methyl]-trimethylsilane Chemical compound C[Si](C)(C)C(F)(F)Br WDZVWBWAUSUTTO-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(z)-but-2-enedioic acid Chemical compound CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- AEMQUICCWRPKDB-UHFFFAOYSA-N acetic acid;cyclohexane-1,2-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1CCCCC1C(O)=O AEMQUICCWRPKDB-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940054685 alinia Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 229940002637 baraclude Drugs 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229950004237 birinapant Drugs 0.000 description 1
- 108010063132 birinapant Proteins 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940124765 capsid inhibitor Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940074057 epivir hbv Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 1
- SQGRDKSRFFUBBU-UHFFFAOYSA-N ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholin-4-ylmethyl)-2-(1,3-thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1C(C=2SC=CN=2)=NC(C=2C(=CC(F)=CC=2)Br)C(C(=O)OCC)=C1CN1CCOCC1 SQGRDKSRFFUBBU-UHFFFAOYSA-N 0.000 description 1
- MEUSJJFWVKBUFP-UHFFFAOYSA-N ethyl 5-amino-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C)C=1N MEUSJJFWVKBUFP-UHFFFAOYSA-N 0.000 description 1
- YPXGHKWOJXQLQU-UHFFFAOYSA-N ethyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1N YPXGHKWOJXQLQU-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940097709 hepsera Drugs 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- KJDJPXUIZYHXEZ-UHFFFAOYSA-N hydrogen sulfate;methylaminoazanium Chemical compound CN[NH3+].OS([O-])(=O)=O KJDJPXUIZYHXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical class C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 1
- FVNJBPMQWSIGJK-HNNXBMFYSA-N methyl (4r)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate Chemical compound C1([C@@H]2N=C(NC(C)=C2C(=O)OC)C=2C(=CC(F)=CN=2)F)=CC=C(F)C=C1Cl FVNJBPMQWSIGJK-HNNXBMFYSA-N 0.000 description 1
- XLKDKHRGIJWOSN-UHFFFAOYSA-N methyl 4-bromo-3-methoxybenzoate Chemical compound COC(=O)C1=CC=C(Br)C(OC)=C1 XLKDKHRGIJWOSN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- WVKNBCACIPKHEW-UHFFFAOYSA-N n,n-diethylethanamine;n,n-dimethylformamide Chemical compound CN(C)C=O.CCN(CC)CC WVKNBCACIPKHEW-UHFFFAOYSA-N 0.000 description 1
- OQIUTYABZMBBME-FMQUCBEESA-N n-[(e)-1-bromo-1-(2-methoxyphenyl)-3-oxo-3-piperidin-1-ylprop-1-en-2-yl]-4-nitrobenzamide Chemical compound COC1=CC=CC=C1\C(Br)=C(C(=O)N1CCCCC1)/NC(=O)C1=CC=C([N+]([O-])=O)C=C1 OQIUTYABZMBBME-FMQUCBEESA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical class CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 125000005342 perphosphate group Chemical group 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- ZGYXGRYOQNEDDB-UHFFFAOYSA-N tert-butyl 4-[5-[5-amino-4-[(3-chloro-4-fluorophenyl)carbamoyl]-1-methylpyrazol-3-yl]-1,2,3,3a,4,5,6,6a-octahydropentalen-2-yl]imidazole-1-carboxylate Chemical compound NC1=C(C(=NN1C)C1CC2CC(CC2C1)C=1N=CN(C=1)C(=O)OC(C)(C)C)C(NC1=CC(=C(C=C1)F)Cl)=O ZGYXGRYOQNEDDB-UHFFFAOYSA-N 0.000 description 1
- LMLHFGLXLPDQTG-UHFFFAOYSA-N tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,3a,6,6a-tetrahydro-1h-cyclopenta[c]pyrrole-2-carboxylate Chemical compound C=1C2CN(C(=O)OC(C)(C)C)CC2CC=1B1OC(C)(C)C(C)(C)O1 LMLHFGLXLPDQTG-UHFFFAOYSA-N 0.000 description 1
- GGNDIMLSSMWKDR-UHFFFAOYSA-N tert-butyl 5-oxo-1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(=O)CC2CN(C(=O)OC(C)(C)C)CC21 GGNDIMLSSMWKDR-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940063032 tyzeka Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
本願は、2018年10月22日に出願された米国特許仮出願第62/748,906号、および2019年6月7日に出願された米国仮特許出願第62/858,790号の利益を主張し、これらの全内容は本明細書に参照により組み込まれる。
B型肝炎ウイルス(HBV)は、ウイルス性肝炎を引き起こし、この肝炎はさらに、慢性肝疾患を招き得、肝硬変および肝臓がん(肝細胞癌)のリスクを高め得る。世界的に、約20億人がHBVに感染しており、約3億6千万人が慢性的に感染しており、毎年、HBV感染症による死亡者は50万人を超える。HBVは、体液によって母親から子どもへ、***によって、および血液製剤を介して伝播し得る。また、HBV陽性の母親から生まれた子どもは、誕生時にワクチン接種しない限り、感染し得る。
本開示は、部分的に、HBVコアタンパク質集合体の破壊に有用な、5員ヘテロアリールカルボキサミド化合物およびその医薬組成物、ならびにHBV感染症を処置する方法を提供する。
ここで、本開示の特徴および他の詳細を、より具体的に記載する。本開示をさらに記載する前に、本明細書、実施例および添付の特許請求の範囲に用いられているある特定の用語を、ここにまとめる。これらの定義は、本開示の残りを考慮し、当業者によって理解される通りに読み取られるべきである。別段定義されない限り、本明細書で使用されるあらゆる技術的および科学的用語は、当業者によって一般に理解されるものと同じ意味を有する。
「アルケニル」という用語は、本明細書で使用される場合、少なくとも1つの炭素-炭素二重結合を有する不飽和の直鎖または分岐の炭化水素を指す。例示的なアルケニル基として、本明細書でC2~6アルケニルと呼ばれる、2~6個の炭素原子の直鎖または分岐の基が挙げられるが、これらに限定されない。例示的なアルケニル基として、ビニル、アリル、ブテニル、ペンテニルなどが挙げられるが、これらに限定されない。
「シアノ」という用語は、本明細書で使用される場合、基-CNを指す。
「シクロアルキル」という用語は、本明細書で使用される場合、例えば、本明細書でC3~6モノシクロアルキルと呼ばれる3~6個の炭素の飽和の単環式炭化水素基、または、例えば、本明細書でC8~12ビシクロアルキルと呼ばれる8~12個の炭素の二環式炭化水素環構造を指す。二環式シクロアルキル基に関して、2つの環は、同じまたは異なる炭素を介して結合されてよい。例示的な単環式シクロアルキル基として、シクロヘキシル、シクロペンチル、シクロペンテニル、シクロブチルおよびシクロプロピルが挙げられるが、これらに限定されない。例示的な二環式シクロアルキル基として、スピロ[2.5]オクタニル、スピロ[3.5]ノナニル、ビシクロ[2.2.2]オクタニル、ビシクロ[4.1.0]ヘプタニル、オクタヒドロペンタレニル、ビシクロ[4.2.0]オクタニル、ビシクロ[1.1.1]ペンタニル、ビシクロ[2.2.1]ヘプタニル、およびビシクロ[2.2.2]オクタニルが挙げられるが、これらに限定されない。
「ハロアルキル」という用語は、本明細書で使用される場合、1個または複数のハロゲン原子で置換されているアルキル基を指す。例えば、ハロC1~6アルキルは、1個または複数のハロゲン原子で置換されている1~6個の炭素原子の直鎖または分枝のアルキル基を指す。例として、CH2F-、CHCl2-、-CHF2、CF3-、CF3CH2-、CH3CF2、CF3CCl2-およびCF3CF2-が挙げられるが、これらに限定されない。
「ヒドロキシアルキル」という用語は、本明細書で使用される場合、1つまたは複数のヒドロキシ基で置換されているアルキル基を指す。例として、HOCH2-、HOCH2CH2-、CH3CH(OH)CH2-およびHOCH2CH(OH)CH2-が挙げられるが、これらに限定されない。
本明細書で使用される場合、例えば、
一態様では、本開示は、式Iの化合物
X1はNRx1、OまたはSであり、
X2はNまたはCRx2であり、
X3はO、NR7、CR4R8、C(O)、S(O)t、C=CR4R0またはC=NR4であり、
X4およびX6は、独立して、OまたはSであり、
X5はO、SまたはNR0であり、
Lは結合またはC1~6アルキレンであり、
L1は、結合、C1~6アルキレン、O、NRc、C(O)、C(O)NRc、S(O)tまたはS(O)tNRcであり、
Rx1およびRx2は、水素、C1~6アルキル、ハロC1~6アルキルおよびC3~6モノシクロアルキルからなる群から独立して選択され、
Ra、RbおよびRcは、水素、C1~6アルキル、ハロC1~6アルキルおよびC3~6モノシクロアルキルからなる群から出現するごとに独立して選択され、
Rdは水素、OH、C1~6アルキルまたはC1~6アルコキシであり、
R0、R6、R8およびR11は、水素、ハロゲン、OH、CN、NO2、オキソ、RdN=、ヒドラジノ、ホルミル、アジド、シリル、シロキシ、HOC(O)-、RaRbN-、RaRbNS(O)t-、C1~6アルキル、C2~6アルケニル、C2~6アルキニル、C3~6モノシクロアルキル、ハロC1~6アルキル、ヒドロキシC1~6アルキル-、RaRbNC1~6アルキル-、HOC(O)C1~6アルキル-、RaRbNC1~6アルキルNRc-、C1~6アルキルNRaC1~6アルキルNRc-、C1~6アルコキシ、ハロC1~6アルコキシ、ヒドロキシC1~6アルコキシ-、RaRbNC1~6アルコキシ-、C1~6アルコキシC1~6アルキル-、ハロC1~6アルコキシC1~6アルキル-、RaRbNC(O)-、C1~6アルキルC(O)-、C1~6アルコキシC(O)-、C1~6アルキルC(O)O-、C1~6アルキルS(O)q-、C1~6アルキルS(O)tNRc-、C1~6アルキルS(O)tC1~6アルキル-、C1~6アルキルS(O)tNRaC1~6アルキル-、C3~6シクロアルキルS(O)tC1~6アルキル-、C1~6アルキルC(O)C1~6アルキル-、およびC1~6アルキルC(O)OC1~6アルキル-からなる群から出現するごとに独立して選択され、
R0aは、水素、ハロゲン、OH、CN、NO2、RaRbN-、C1~6アルキルおよびハロC1~6アルキルからなる群から出現するごとに独立して選択され、
R1は、フェニル、ナフチル、C3~6モノシクロアルキル、C3~6モノヘテロシクロアルキル、または5~6員の単環式ヘテロアリールであり、前記フェニル、C3~6モノシクロアルキル、C3~6モノヘテロシクロアルキル、または5~6員の単環式ヘテロアリールは、1、2、または3個の、独立して選択されるR11基で必要に応じて置換されており、
R2は、水素、ハロゲン、RaRbN、C1~6アルキル、ハロC1~6アルキル、C3~6モノシクロアルキルまたはC1~6アルコキシであり、
R3は、
R4は、R5、R6もしくはR5-L1-であるか、
またはR4およびR8は、それらが結合している炭素原子と一緒になって
R4aは水素またはC1~6アルキルであり、
R4bはR5、R5a、R6またはR5-L1-であり、
R5は、
R5aは
R5bは、
R6aは水素またはC1~6アルキルであり、
R7は、水素、C1~6アルキル、C1~6ハロアルキル、C1~6アルコキシC1~6アルキル-、NRaRbC(O)-、R7aC(O)-、C1~6アルキルオキシC(O)-、C1~6アルキルS(O)q-またはC1~6ハロアルキルS(O)q-であり、
R7aは、C1~6アルキルまたはC3~6モノシクロアルキルであり、
q、r、t、およびwは、0、1および2から出現するごとに独立して選択され、
vは、0、1、2および3から出現するごとに独立して選択される]
を提供する。
X1はNRx1、OまたはSであり、
X2はNまたはCRx2であり、
X3はO、NR7、CR4R8、C(O)、S(O)t、C=CR4R0またはC=NR4であり、
X4は、OまたはSであり、
X5はO、SまたはNR0であり、
Lは結合またはC1~6アルキレンであり、
L1は、結合、C1~6アルキレン、O、NRc、C(O)、C(O)NRc、S(O)tまたはS(O)tNRcであり、
Rx1およびRx2は、水素、C1~6アルキル、ハロC1~6アルキルおよびC3~6モノシクロアルキルからなる群から独立して選択され、
Ra、RbおよびRcは、水素、C1~6アルキル、ハロC1~6アルキルおよびC3~6モノシクロアルキルからなる群から出現するごとに独立して選択され、
Rdは水素、OH、C1~6アルキルまたはC1~6アルコキシであり、
R0、R6、R8およびR11は、水素、ハロゲン、OH、CN、NO2、オキソ、RdN=、ヒドラジノ、ホルミル、アジド、シリル、シロキシ、HOC(O)-、RaRbN-、RaRbNS(O)t-、C1~6アルキル、C2~6アルケニル、C2~6アルキニル、C3~6モノシクロアルキル、ハロC1~6アルキル、ヒドロキシC1~6アルキル-、RaRbNC1~6アルキル-、HOC(O)C1~6アルキル-、RaRbNC1~6アルキルNRc-、C1~6アルキルNRaC1~6アルキルNRc-、C1~6アルコキシ、ハロC1~6アルコキシ、ヒドロキシC1~6アルコキシ-、RaRbNC1~6アルコキシ-、C1~6アルコキシC1~6アルキル-、ハロC1~6アルコキシC1~6アルキル-、RaRbNC(O)-、C1~6アルキルC(O)-、C1~6アルコキシC(O)-、C1~6アルキルC(O)O-、C1~6アルキルS(O)q-、C1~6アルキルS(O)tNRc-、C1~6アルキルS(O)tC1~6アルキル-、C1~6アルキルS(O)tNRaC1~6アルキル-、C3~6シクロアルキルS(O)tC1~6アルキル-、C1~6アルキルC(O)C1~6アルキル-、およびC1~6アルキルC(O)OC1~6アルキル-からなる群から出現するごとに独立して選択され、
R1は、フェニル、ナフチル、C3~6モノシクロアルキル、C3~6モノヘテロシクロアルキル、または5~6員の単環式ヘテロアリールであり、前記フェニル、C3~6モノシクロアルキル、C3~6モノヘテロシクロアルキル、または5~6員の単環式ヘテロアリールは、1、2、または3個の、独立して選択されるR11基で必要に応じて置換されており、
R2は、水素、ハロゲン、RaRbN、C1~6アルキル、ハロC1~6アルキル、C3~6モノシクロアルキルまたはC1~6アルコキシであり、
R3は、
R4は、R5、R6もしくはR5-L1-であり、
R4aは水素またはC1~6アルキルであり、
R5は、
R6aは水素またはC1~6アルキルであり、
R7は、水素、C1~6アルキル、C1~6ハロアルキル、C1~6アルコキシC1~6アルキル-、NRaRbC(O)-、R7aC(O)-、C1~6アルキルオキシC(O)-、C1~6アルキルS(O)q-またはC1~6ハロアルキルS(O)q-であり、
R7aは、C1~6アルキルまたはC3~6モノシクロアルキルであり、
q、r、t、およびwは、0、1および2から出現するごとに独立して選択され、
vは、0、1、2および3から出現するごとに独立して選択される]
を提供する。
ある特定の実施形態では、X1はNRx1であり、X2はNである。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルまたは水素である。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルである。
ある特定の実施形態では、X1はOであり、X2はNである。
ある特定の実施形態では、X3はCR4R8である。
ある特定の実施形態では、Lは結合である。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合である。
ある特定の実施形態では、LはC1~6アルキレンである。
ある特定の実施形態では、L1は結合である。
ある特定の実施形態では、L1はC1~6アルキレンである。
ある特定の実施形態では、R1は、
R11は、ハロゲン、CN、C1~6アルキルおよびハロC1~6アルキルからなる群から出現するごとに独立して選択され、
z1は、0、1、2または3である]である。
ある特定の実施形態では、R11は、ハロゲンおよびCNからなる群から出現するごとに独立して選択される。
ある特定の実施形態では、R11は、F、Cl、BrおよびIからなる群から出現するごとに独立して選択される。
ある特定の実施形態では、R1は、
ある特定の実施形態では、R1は、
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
ある特定の実施形態では、R1は、
R11は、ハロゲン、CN、C1~6アルキル、およびハロC1~6アルキルからなる群から出現するごとに独立して選択され、
z1は、0、1、2または3である]である。
ある特定の実施形態では、R1は、ハロゲン、CN、C1~6アルキル、およびハロC1~6アルキルからなる群から独立して選択される1、2、または3個の置換基で必要に応じて置換されているC3~6モノヘテロシクロアルキルである。
R11は、水素、ハロゲン、CN、C1~6アルキル、およびハロC1~6アルキルからなる群から出現するごとに独立して選択され、
R12は水素またはC1~6アルキルであり、
X6はOまたはSであり、
z1は、0、1、2または3であり、
z2は、0、1または2である]である。
ある特定の実施形態では、R1は、ハロゲン、CN、C1~6アルキル、およびハロC1~6アルキルからなる群から独立して選択される1、2、または3個の置換基で必要に応じて置換されている5~6員の単環式ヘテロアリールである。
R11は、ハロゲン、CN、C1~6アルキルおよびハロC1~6アルキルからなる群から出現するごとに独立して選択され、
z1は、0、1、2または3である]である。
ある特定の実施形態では、R2はRaRbNである。
ある特定の実施形態では、R2はRaRbNであり、RaおよびRbは、水素およびC1~6アルキルからなる群から独立して選択される。
ある特定の実施形態では、R2はNH2である。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R4はR5である。
ある特定の実施形態では、R4はR6である。
ある特定の実施形態では、R4はR5-L1-である。
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
ある特定の実施形態では、R5は、
ある特定の実施形態では、R6はC1~6アルキルS(O)tC1~6アルキル-またはC1~6アルキルS(O)tNRaC1~6アルキル-である。
ある特定の実施形態では、R6はC1~6アルキルS(O)tC1~6アルキル-である。
ある特定の実施形態では、R6はC1~6アルキルS(O)tC1~6アルキル-であり、tは1または2である。
ある特定の実施形態では、R6はC1~6アルキルS(O)tC1~6アルキル-であり、tは2である。
ある特定の実施形態では、R8は水素、OHまたはC1~6アルコキシである。
ある特定の実施形態では、R8はOHである。
ある特定の実施形態では、R3は、
ある特定の実施形態では、R3は、
R6はC1~6アルキルS(O)tC1~6アルキル-またはC1~6アルキルS(O)tNRaC1~6アルキル-であり、
R8は水素、OHまたはC1~6アルコキシである。
ある特定の実施形態では、R3は、
R6はC1~6アルキルS(O)tC1~6アルキル-であり、
R8は水素、OHまたはC1~6アルコキシである。
ある特定の実施形態では、R3は、
R6はC1~6アルキルS(O)tC1~6アルキル-であり、
R8はOHである。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
R6はC1~6アルキルS(O)tC1~6アルキル-またはC1~6アルキルS(O)tNRaC1~6アルキル-であり、
R8は水素、OHまたはC1~6アルコキシである。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
R6はC1~6アルキルS(O)tC1~6アルキル-であり、
R8は水素、OHまたはC1~6アルコキシである。
ある特定の実施形態では、X1はNRx1であり、X2はNであり、Rx1はメチルであり、Lは結合であり、R1は、
R6はC1~6アルキルS(O)tC1~6アルキル-であり、
R8はOHである。
別の態様では、本開示は、式Iの化合物、またはその薬学的に許容される塩、および薬学的に許容される賦形剤を含む医薬組成物を提供する。特に、本開示は、1種または複数種の薬学的に許容される担体と一緒に製剤化される、本明細書で開示されているような化合物を含む医薬組成物を提供する。これらの製剤には、経口、直腸、局所的、口腔内頬側、非経口(例えば、皮下、筋肉内、皮内、または静脈内)、直腸、経膣、またはエアゾール投与に適したものが含まれるが、いかなる場合でも、最も適切な投与形態は、処置を受ける状態の程度および重症度ならびに使用される特定の化合物の性質に依存することになる。例えば、開示された組成物は、単位用量として製剤化してもよいし、および/または経口もしくは皮下投与用に製剤化してもよい。
さらなる一態様では、B型肝炎感染症の処置を必要とする患者のB型肝炎感染症を処置する方法であって、有効量の開示される化合物を対象もしくは患者に投与から選択する、ならびに/または開示される第1の化合物、および必要に応じて、開示される追加の異なる化合物(複数可)を投与するステップを含む方法が提供される。別の実施形態では、B型肝炎感染症の処置を必要とする患者のB型肝炎感染症を処置する方法であって、治療有効量の開示された医薬組成物あるいは開示された化合物または2種もしくはそれよりも多くの開示された化合物、および薬学的に許容される賦形剤を含む医薬組成物を、対象または患者に投与するステップを含む方法が提供される。
本明細書に記載される化合物は、本明細書に含有されている教示および当技術分野で公知の合成手順に基づいて、いくつかの方式で調製することができる。下記の合成法の説明において、溶媒、反応雰囲気、反応温度、実験期間および後処理手順の選択を含めた、提唱されるあらゆる反応条件は、別段指定されない限り、その反応に対して標準の条件となるように選択できることを理解されたい。分子の様々な部分上に存在する官能基は、提唱された試薬および反応と適合すべきであることが、有機合成の当業者によって理解される。反応条件と適合性がない置換基は、当業者に明らかであり、したがって代替方法が示される。実施例のための出発材料は、市販されているか、または標準の方法によって公知の材料から容易に調製される。
略語:
DCM ジクロロメタン
EtOAc 酢酸エチル
MeOH メタノール
DMSO ジメチルスルホキシド
ACN アセトニトリル
DIAD アゾジカルボン酸ジイソプロピル
DIEA ジイソプロピルエチルアミン
nBuLi n-ブチルリチウム
iPrOH イソプロパノール
AcOH 酢酸
BOC2O 二炭酸ジ-tert-ブチル
Et3N トリエチルアミン
DMF N,N-ジメチルホルムアミド
THF テトラヒドロフラン
TEA トリエチルアミン
TFA トリフルオロ酢酸
TLC 薄層クロマトグラフィー
LCMS 液体クロマトグラフィー-質量分析法
HPLC 高速液体クロマトグラフィー
XPhos 2-ジシクロヘキシルホスフィノ-2’,4’,6’-トリイソプロピルビフェニル
DPPF 1,1’-ビス(ジフェニルホスフィノ)フェロセン
NMO N-メチルモルホリン-N-オキシド
HATU ヘキサフルオロホスフェートアザベンゾトリアゾールテトラメチルウロニウム)
SFC 超臨界流体クロマトグラフィー
NBS N-ブロモスクシンイミド
合成のさらなる方法がスキームVIに例示されている。中間体IV-5は、公知の条件を使用して、対応するエポキシドVI-1に変換することができる。様々な求核剤(NucH、VI-2)とのその反応を介して、この中間体を変換することによって、VI-3で表される化合物を形成することができる。VI-3が硫化物の場合、硫黄原子を対応するスルホンVI-5へと酸化させることにより、さらなる修飾を達成することができる。VI-5を形成するための第2の方法は、IV-5をスルホンアミドVI-4のスルホンの対応するアニオンと反応させることを含む。VI-5およびVI-3は、スキームに例示されているように、少なくとも4つ異なるジアステレオマー立体配置で存在することができる。反応条件および経路は、他のジアステレオマーよりもあるジアステレオマーの形成を好む公知の立体選択的反応原理に基づき選択することができる。加えて、VI-3およびVI-5の個々のジアステレオマーは、公知の条件を使用した単離の対象となる。
中間体19~23。中間体19~23を中間体18について記載されている手順に従い合成した。
中間体25~26。中間体25~26を中間体24について記載されている手順に従い合成した。
中間体28~38。中間体28~38を中間体27について記載されている手順に従い合成した。
表1.表1の化合物をCP-AIA-202A-Dについて記載されている手順に従い合成した。
表2.表2の化合物をAIA-352-1およびAIA-352-2について記載されている手順に従い合成した。
表3.表3の化合物をAIA-150-CおよびAIA-150-Dについて記載されている手順に従い合成した。
表4.表4の化合物を、5-アミノ-N-(3-クロロ-4-フルオロフェニル)-1-メチル-3-(5-(メチルチオ)オクタヒドロペンタレン-2-イル)-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表5. 表5の化合物を、5-アミノ-N-(3-クロロ-4-フルオロフェニル)-1-メチル-3-(5-(メチルスルホニル)オクタヒドロペンタレン-2-イル)-1H-ピラゾール-4-カルボキサミドおよび5-アミノ-N-(3-クロロ-4-フルオロフェニル)-1-メチル-3-(5-(メチルスルフィニル)オクタヒドロペンタレン-2-イル)-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表6. 表6の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-(5-(ジメチルアミノ)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表7. 表7の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-1-メチル-3-(5-(メチルアミノ)オクタヒドロペンタレン-2-イル)-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表8.表8の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-(5-ヒドロキシ-5-(メチルチオメチル)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表9.表9の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-((2r,5r)-5-ヒドロキシ-5-(メチルスルホニルメチル)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミド(AIA-227-1)および5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-((2s,5s)-5-ヒドロキシ-5-(メチルスルホニルメチル)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミド(AIA-227-2)について記載されている手順に従い合成した。
2(50.0mg、0.08mmol)、モルホリン(14.0mg、0.16mmol)およびK2CO3(22.1mg、0.16mmol)のACN中混合物を80℃で撹拌した。反応の完了後、混合物をH2Oでクエンチし、DCMで抽出した。有機層を減圧下で除去し、残渣を分取HPLCで精製して、白色の固体として、5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-(5-ヒドロキシ-5-(((3-モルホリノプロピル)スルホニル)メチル)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミド、ジアステレオマー1(AIA-295-B)(33mg、55.2%)を得た。MS計算値:597.22; MS実測値:598.2 [M+1]+ ; 1H NMR (DMSO-d6, 400 MHz): δ 8.95 (s, 1H), 7.91 (dd, J=2.4 Hz, 6.8 Hz, 1H), 7.54-7.50 (m, 1H), 7.35 (t, J=9.2 Hz, 1H), 5.97(s, 2H), 4.78(s, 1H), 3.57-3.54 (m, 5H), 3.49 (s, 3H), 3.32 (brs, 2H), 3.16-3.12 (m, 2H), 2.63-2.61 (m, 2H), 2.36-2.33 (m, 6H), 2.18-2.11 (m, 2H), 2.06-2.01 (m, 2H), 1.85-1.81 (m, 2H), 1.47-1.36 (m, 4H).
表10. 表10の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-(5-ヒドロキシ-5-(((3-モルホリノプロピル)スルホニル)メチル)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミド、ジアステレオマー1および2について記載されている手順に従い合成した。
表11.表11の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-(5-ヒドロキシ-5-(イソプロポキシメチル)オクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表12.表12の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-3-(5-ヒドロキシ-5-イソプロピルオクタヒドロペンタレン-2-イル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表13.表13の化合物を5-アミノ-3-(5-カルバモイルオクタヒドロペンタレン-2-イル)-N-(3-クロロ-4-フルオロフェニル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表14. 表14の化合物を5-アミノ-3-(5-カルバモイルオクタヒドロペンタレン-2-イル)-N-(3-クロロ-4-フルオロフェニル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
表15. 表15の化合物を3-(2-アセチルオクタヒドロシクロペンタ[c]ピロール-5-イル)-5-アミノ-N-(3-クロロ-4-フルオロフェニル)-1-メチル-1H-ピラゾール-4-カルボキサミドについて開示された手順に従い合成した。
表16.表16の化合物を5-アミノ-N-(3-クロロ-4-フルオロフェニル)-1-メチル-3-(5-(1-メチル-1H-ピラゾール-4-イル)オクタヒドロペンタレン-2-イル)-1H-ピラゾール-4-カルボキサミドについて記載されている手順に従い合成した。
HepAD38細胞からのウイルス産生に対する試験化合物の活性を測定するアッセイ
成長培地(DMEM/F12(1:1)(Hyclone、カタログ番号:SH30023.02)、1×Pen/Strep(Invitrogen、カタログ番号:15140-122)、10%FBS(Tissue Culture Biologics、カタログ番号:101)、250μg/mLのG418(Alfa Aesar、カタログ番号:J62671)、1μg/mLのテトラサイクリン(Teknova、カタログ番号:T3320))を含むT-150フラスコ(Corning、カタログ番号:430825)内で成長したHepAD38細胞を、0.25%トリプシン-EDTA(Invitrogen、カタログ番号:25200-056)を用いて剥離した。次いで、テトラサイクリンを含まない処理培地(15mLのDMEM/F12(1:1)、1×Pen/Strep、2%FBS入り、認可されたTet-system(Clontech、カタログ番号:631106))をミックスに加え、50mlコニカルチューブ(Falcon、カタログ番号:21008-918)に移し、1300rpmで5分間回転させた。次いで、ペレット化した細胞を、50mLの1×DPBS(Invitrogen、カタログ番号:14190-136)で2回、50mLの処理培地で2回再懸濁/洗浄した。次いで、HepAD38細胞を10mLの処理培地に再懸濁させ、シリンジに入れ、カウントした。96ウェルの透明底TCプレート(Corning、カタログ番号:3904)のウェルに、180μLの処理培地中の50,000個の細胞/ウェルを播種し、10%DMSO(Sigma、カタログ番号:D4540)を対照として、または処理培地中の試験化合物の10%DMSO中10×溶液を、20μLで、10μMから開始する最終化合物濃度になるように加え、5%CO2インキュベーター内、37℃で5日間プレートをインキュベートした。
揮散の20日後、0.08×0.10×0.20mmのサイズを有する化合物AIA-227-2の結晶をEtOHから得、X線回折データ収集のために使用した。ω/φスキャンモードでCuKα放射線を使用して、室温で、Bruker SMART CCD領域-検出器回折計でデータを収集した。10846の反射を収集し、このうち3754の反射は独特であった(Rint=0.0507)。
以下に列挙される項目を含めた、本明細書で言及されたあらゆる刊行物および特許文書は、あたかもそれぞれの個々の刊行物または特許文書が、参照によって具体的に個々に組み込まれるかのように、それらの全体があらゆる目的で参照によって本明細書に組み込まれる。矛盾が生じた場合、本明細書の任意の定義を含めて、本願が優先する。
本開示の具体的な実施形態を論じてきたが、先の明細書は、例示的であり、制限的なものではない。本開示の多くの変更形態が、本明細書を再考察する際に、当業者に明らかとなろう。本開示の完全な範囲は、特許請求の範囲を、それらの均等物の完全な範囲と共に参照し、本明細書を、このような変更形態と共に参照することによって決定されるべきである。
Claims (27)
- 一態様では、本開示は、式Iの化合物
X1はNRx1、OまたはSであり、
X2はNまたはCRx2であり、
X3はO、NR7、CR4R8、C(O)、S(O)t、C=CR4R0またはC=NR4であり、
X4およびX6は、独立して、OまたはSであり、
X5はO、SまたはNR0であり、
Lは結合またはC1~6アルキレンであり、
L1は、結合、C1~6アルキレン、O、NRc、C(O)、C(O)NRc、S(O)tまたはS(O)tNRcであり、
Rx1およびRx2は、水素、C1~6アルキル、ハロC1~6アルキルおよびC3~6モノシクロアルキルからなる群から独立して選択され、
Ra、RbおよびRcは、水素、C1~6アルキル、ハロC1~6アルキルおよびC3~6モノシクロアルキルからなる群から出現するごとに独立して選択され、
Rdは水素、OH、C1~6アルキルまたはC1~6アルコキシであり、
R0、R6、R8およびR11は、水素、ハロゲン、OH、CN、NO2、オキソ、RdN=、ヒドラジノ、ホルミル、アジド、シリル、シロキシ、HOC(O)-、RaRbN-、RaRbNS(O)t-、C1~6アルキル、C2~6アルケニル、C2~6アルキニル、C3~6モノシクロアルキル、ハロC1~6アルキル、ヒドロキシC1~6アルキル-、RaRbNC1~6アルキル-、HOC(O)C1~6アルキル-、RaRbNC1~6アルキルNRc-、C1~6アルキルNRaC1~6アルキルNRc-、C1~6アルコキシ、ハロC1~6アルコキシ、ヒドロキシC1~6アルコキシ-、RaRbNC1~6アルコキシ-、C1~6アルコキシC1~6アルキル-、ハロC1~6アルコキシC1~6アルキル-、RaRbNC(O)-、C1~6アルキルC(O)-、C1~6アルコキシC(O)-、C1~6アルキルC(O)O-、C1~6アルキルS(O)q-、C1~6アルキルS(O)tNRc-、C1~6アルキルS(O)tC1~6アルキル-、C1~6アルキルS(O)tNRaC1~6アルキル-、C3~6シクロアルキルS(O)tC1~6アルキル-、C1~6アルキルC(O)C1~6アルキル-、およびC1~6アルキルC(O)OC1~6アルキル-からなる群から出現するごとに独立して選択され、
R0aは、水素、ハロゲン、OH、CN、NO2、RaRbN-、C1~6アルキルおよびハロC1~6アルキルからなる群から出現するごとに独立して選択され、
R1は、フェニル、ナフチル、C3~6モノシクロアルキル、C3~6モノヘテロシクロアルキル、または5~6員の単環式ヘテロアリールであり、前記フェニル、C3~6モノシクロアルキル、C3~6モノヘテロシクロアルキル、または5~6員の単環式ヘテロアリールは、1、2、または3個の、独立して選択されるR11基で必要に応じて置換されており、
R2は、水素、ハロゲン、RaRbN、C1~6アルキル、ハロC1~6アルキル、C3~6モノシクロアルキルまたはC1~6アルコキシであり、
R3は、
R4は、R5、R6もしくはR5-L1-であるか、
またはR4およびR8は、それらが結合している炭素原子と一緒になって
R4aは水素またはC1~6アルキルであり、
R4bはR5、R5a、R6またはR5-L1-であり、
R5は、
R5aは
R5bは、
R6aは水素またはC1~6アルキルであり、
R7は、水素、C1~6アルキル、C1~6ハロアルキル、C1~6アルコキシC1~6アルキル-、NRaRbC(O)-、R7aC(O)-、C1~6アルキルオキシC(O)-、C1~6アルキルS(O)q-またはC1~6ハロアルキルS(O)q-であり、
R7aは、C1~6アルキルまたはC3~6モノシクロアルキルであり、
q、r、t、およびwは、0、1および2から出現するごとに独立して選択され、
vは、0、1、2および3から出現するごとに独立して選択される]
を提供する。 - X1がNRx1であり、X2がNであり、Rx1が水素またはメチルである、請求項1に記載の化合物、またはその薬学的に許容される塩。
- Rx1がメチルである、請求項1または2に記載の化合物、またはその薬学的に許容される塩。
- Lが結合である、請求項1から3のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- L1が結合である、請求項1から3のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- R2がRaRbNである、請求項1から5のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- R2がNH2である、請求項6に記載の化合物、またはその薬学的に許容される塩。
- 出現するごとに、R11が、F、Cl、BrおよびIからなる群から独立して選択される、請求項8に記載の化合物、またはその薬学的に許容される塩。
- R6がC1~6アルキルS(O)tC1~6アルキル-またはC1~6アルキルS(O)tNRaC1~6アルキル-である、請求項18または19に記載の化合物、またはその薬学的に許容される塩。
- R6がC1~6アルキルS(O)tC1~6アルキル-であり、tが1または2である、請求項20に記載の化合物、またはその薬学的に許容される塩。
- tが2である、請求項21に記載の化合物、またはその薬学的に許容される塩。
- R8が、水素、OHまたはC1~6アルコキシである、請求項18から22のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- R8がOHである、請求項23に記載の化合物、またはその薬学的に許容される塩。
- 請求項1から24のいずれか一項に記載の化合物、またはその薬学的に許容される塩、および薬学的に許容される賦形剤を含む医薬組成物。
- B型肝炎(HBV)感染症を処置することを必要とする対象においてHBV感染症を処置する方法であって、前記対象に、治療有効量の請求項1から24のいずれか一項に記載の化合物、またはその薬学的に許容される塩を投与することを含む方法。
- B型肝炎(HBV)感染症を処置することを必要とする対象においてHBV感染症を処置する方法であって、前記対象に、治療有効量の請求項25の医薬組成物を投与することを含む方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862748906P | 2018-10-22 | 2018-10-22 | |
US62/748,906 | 2018-10-22 | ||
US201962858790P | 2019-06-07 | 2019-06-07 | |
US62/858,790 | 2019-06-07 | ||
PCT/US2019/057362 WO2020086533A1 (en) | 2018-10-22 | 2019-10-22 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022508953A true JP2022508953A (ja) | 2022-01-19 |
JPWO2020086533A5 JPWO2020086533A5 (ja) | 2023-06-22 |
Family
ID=68610300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021547054A Pending JP2022508953A (ja) | 2018-10-22 | 2019-10-22 | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11560370B1 (ja) |
EP (1) | EP3870296A1 (ja) |
JP (1) | JP2022508953A (ja) |
KR (1) | KR20210095143A (ja) |
CN (1) | CN113195055A (ja) |
AU (1) | AU2019364352A1 (ja) |
BR (1) | BR112021007602A2 (ja) |
CA (1) | CA3117449A1 (ja) |
IL (1) | IL282433A (ja) |
MA (1) | MA53983A (ja) |
MX (1) | MX2021004580A (ja) |
PH (1) | PH12021550887A1 (ja) |
SG (1) | SG11202104086PA (ja) |
TW (1) | TW202028190A (ja) |
WO (1) | WO2020086533A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111205264A (zh) * | 2020-02-25 | 2020-05-29 | 成都睿智化学研究有限公司 | 一种合成同位羟基和甲磺酰甲基化合物的新方法 |
EP4139000A1 (en) * | 2020-04-22 | 2023-03-01 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023067517A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | Novel crystalline forms |
WO2023105481A1 (en) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス.ブルームバーグ インスティテュート | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
AU2013207205B2 (en) | 2012-01-06 | 2017-02-02 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B |
BR112015004205B1 (pt) | 2012-08-28 | 2022-02-01 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto |
PT2890683T (pt) | 2012-08-28 | 2017-01-17 | Janssen Sciences Ireland Uc | Derivados de sulfamoílo bicíclicos fundidos e a sua utilização como medicamentos para o tratamento da hepatite b |
MX2015002954A (es) | 2012-09-10 | 2015-06-05 | Hoffmann La Roche | Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b. |
AU2013342164A1 (en) | 2012-11-09 | 2015-06-04 | Assembly Biosciences, Inc. | Alternative uses for HBV assembly effectors |
CA2892606A1 (en) | 2012-12-06 | 2014-06-12 | Baruch S. Blumberg Institute | Functionalized benzamide derivatives as antiviral agents against hbv infection |
KR101942151B1 (ko) | 2012-12-27 | 2019-01-24 | 드렉셀유니버시티 | Hbv 감염에 대한 항바이러스 물질 |
SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
EP2981536B1 (en) | 2013-04-03 | 2017-06-14 | Janssen Sciences Ireland UC | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
SG11201509463YA (en) | 2013-05-17 | 2015-12-30 | Hoffmann La Roche | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
ES2695182T3 (es) | 2013-05-17 | 2019-01-02 | Janssen Sciences Ireland Uc | Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B |
DK3024819T3 (en) | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
-
2019
- 2019-10-22 MA MA053983A patent/MA53983A/fr unknown
- 2019-10-22 TW TW108138129A patent/TW202028190A/zh unknown
- 2019-10-22 WO PCT/US2019/057362 patent/WO2020086533A1/en active Application Filing
- 2019-10-22 EP EP19805797.8A patent/EP3870296A1/en active Pending
- 2019-10-22 US US17/287,681 patent/US11560370B1/en active Active
- 2019-10-22 CN CN201980082985.8A patent/CN113195055A/zh active Pending
- 2019-10-22 CA CA3117449A patent/CA3117449A1/en active Pending
- 2019-10-22 SG SG11202104086PA patent/SG11202104086PA/en unknown
- 2019-10-22 JP JP2021547054A patent/JP2022508953A/ja active Pending
- 2019-10-22 MX MX2021004580A patent/MX2021004580A/es unknown
- 2019-10-22 KR KR1020217015135A patent/KR20210095143A/ko unknown
- 2019-10-22 AU AU2019364352A patent/AU2019364352A1/en active Pending
- 2019-10-22 BR BR112021007602-6A patent/BR112021007602A2/pt unknown
-
2021
- 2021-04-19 IL IL282433A patent/IL282433A/en unknown
- 2021-04-21 PH PH12021550887A patent/PH12021550887A1/en unknown
-
2022
- 2022-11-17 US US17/989,237 patent/US20240150324A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA53983A (fr) | 2021-12-15 |
WO2020086533A1 (en) | 2020-04-30 |
KR20210095143A (ko) | 2021-07-30 |
US20240150324A1 (en) | 2024-05-09 |
MX2021004580A (es) | 2021-09-08 |
US11560370B1 (en) | 2023-01-24 |
PH12021550887A1 (en) | 2022-02-21 |
AU2019364352A1 (en) | 2021-06-03 |
TW202028190A (zh) | 2020-08-01 |
EP3870296A1 (en) | 2021-09-01 |
CN113195055A (zh) | 2021-07-30 |
SG11202104086PA (en) | 2021-05-28 |
BR112021007602A2 (pt) | 2021-07-27 |
CA3117449A1 (en) | 2020-04-30 |
IL282433A (en) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7150903B2 (ja) | B型肝炎ウイルスコアタンパク質モジュレーター | |
US10660893B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
JP2022508953A (ja) | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 | |
UA120571C2 (uk) | Алостеричні модулятори нікотинових ацетилхолінових рецепторів | |
US20230183213A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
MX2012006667A (es) | Compuesto de oxadiazol novedosos. | |
US20220081433A1 (en) | Cyclic sulfamide compounds for treatment of hbv | |
US20230002396A1 (en) | Therapeutic compounds | |
EP3846820A1 (en) | Cyclic sulfamide compounds for treatment of hbv | |
US20230295096A1 (en) | Pyrazole carboxamide compounds for treatment of hbv | |
WO2023069547A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
WO2021216661A1 (en) | Pyrazole carboxamide compounds for treatment of hbv | |
RU2799332C2 (ru) | Пиразоло[1,5-a]пиримидинилкарбоксамиды и их применение для лечения патологических состояний | |
WO2023069545A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221021 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230614 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231101 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240126 |